Harm-reduction groups urge expansion of onsite pill testing after surge in fentanyl-contaminated MDMA incidents at festivals

27 October 2026

The calls for expanded onsite pill testing across Australia have intensified after a string of incidents in recent years highlighted the prevalent risk of dangerous adulterants in MDMA pills at music festivals. Harm-reduction advocates cite evidence of worrying trends they claim warrant the need for broader drug-checking programs.

In December 2023, a study of an electronic music festival in Mexico found fentanyl – a highly potent synthetic opioid linked to thousands of overdose deaths in the US and Canada – in 14 of 22 confirmed MDMA samples and 2 of 4 cocaine samples tested. The study's authors warned of the seizure risks of these adulterants and said urgent monitoring and harm-reduction measures were critical at such events.

More recently, the Australian-based SANDAS warned that detection of nitazenes – a newer class of synthetic opioids potentially 40 to 50 times more potent than fentanyl itself – in pills advertised as MDMA underscored the need for similar drug-checking services to be put in place in other Australian states.

"The mere presence of this high-potency, highly dangerous substance, combined with the alarming number of positive results, demonstrates the absolute necessity of pill testing to detect these contaminants before irreparable harm occurs," said SANDAS president Ahren Namatjira.

SANDAS shared an incident report last March from a New South Wales-based harm-reduction group which said onsite medical and public warnings were used to prevent overdoses after a potent synthetic opioid was identified in MDMA tablets at a nearby event.

"The alerts put out by event organisers and festival safety services undoubtedly prevented a catastrophic set of outcomes - saving lives, decreasing pressure on hospital emergency departments and alerting emergency services to this new danger," said Namatjira.

The warnings come as some Australian states have already rolled out various approaches to festival and community-based pill testing. As of earlier this month, Queensland will become the second jurisdiction after the Australian Capital Territory to offer pill testing, with the state government announcing services will be run by a local NGO, The Loop Australia, in partnership with Queensland Injectors Health Network and Queensland Injectors Voice for Advocacy and Action. The rollout will include both fixed-site and festival-based services, although specific locations and dates have not been announced.

Following a pilot last summer which saw 1,648 drug samples tested, the Victorian government has committed to a trial period of up to 18 months. The plan is for both a mobile service to attend music festivals and a dedicated fixed-site at a community health centre, with the service expected to operate starting December 2024.

Meanwhile, New South Wales has allocated a further $4.3 million to run a permanent pill testing program that will visit up to 15 festivals annually, with an existing trial having tested 1,480 samples across 12 events.

However, these initiatives have been criticised as insufficient. In feedback to the 2022-23 parliamentary inquiry on harm minimisation in NSW, The Loop recommended the state also provide fixed-site testing and mobile services to marginalised communities, and not just in festival settings.

The Australian government has previously shown support for pill testing, with a 2019 Greens/David Pocock Bill to legalise the publication of ecstasy testing kits passing the Senate. The Bill stalled in the Lower House, and subsequent efforts to legislate pill testing on a formal basis at a federal level have been unsuccessful.

Internationally, Portugal introduced on-site chemical testing for club drugs as far back as 2001, while Wales has been running a similar pilot for more than a decade. Luxembourg, the Netherlands, Switzerland and Sweden have now followed.

Here, it seems that despite some headway in recent years, the movement to normalise pill testing still has a long way to go. The question remains whether the limited pipeline of exclusively on-site services would be enough to stamp out growing threats, when harmful adulterants are freely available.